Ann: Quarterly Activities and Cashflow Report, page-31

I had a buy order at 0.014 but cancelled it as I have concerns about section 9 estimated outflows of cash for next Qtr ($2.820m). Given the Dec qtr saw "cash expenses and investment of $1.6m" how do they justify $1.2m in extra outgoings without additional orders.
It looks like R&D only gets funding every 6 months?? And given human trials can take years looks like money for mates back home...
CGB need to have a significant amount of good news and orders very soon to ensure its future. IMHO